CA

CanBas Co.,Ltd.

Clinical-stage biopharma developing novel cancer drugs aiming for fewer side effects.

4575 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
沼津市大手町二丁目2番1号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

CanBas Co., Ltd. is a clinical-stage biopharmaceutical company dedicated to the research and development of novel therapeutics for cancer patients. The company focuses on discovering and developing innovative oncology drugs, particularly in the field of immuno-oncology, that target the cell cycle. CanBas utilizes a proprietary screening system to advance its drug pipeline, which includes the clinical-stage candidate CBP501, a calmodulin-modulating peptide. A key objective of its research is to create anticancer treatments with fewer side effects.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-29 08:46
Regulatory News Service
確認書
Japanese 8.1 KB
2025-09-29 08:46
Annual Report
有価証券報告書-第26期(2024/07/01-2025/06/30)
Japanese 576.6 KB
2025-02-13 07:55
Report Publication Announcement
確認書
Japanese 8.1 KB
2025-02-13 07:54
Interim Report
半期報告書-第26期(2024/07/01-2025/06/30)
Japanese 160.4 KB
2024-09-30 08:04
Post-Annual General Meeting Information
臨時報告書
Japanese 22.7 KB
2024-09-27 08:21
Governance Information
内部統制報告書-第25期(2023/07/01-2024/06/30)
Japanese 21.7 KB
2024-09-27 08:21
Registration Form
確認書
Japanese 8.1 KB
2024-09-27 08:20
Annual Report
有価証券報告書-第25期(2023/07/01-2024/06/30)
Japanese 637.2 KB
2024-05-10 08:16
Report Publication Announcement
確認書
Japanese 8.1 KB
2024-05-10 08:16
Quarterly Report
四半期報告書-第25期第3四半期(2024/01/01-2024/03/31)
Japanese 134.6 KB
2024-02-09 08:13
Report Publication Announcement
確認書
Japanese 8.0 KB
2024-02-09 08:12
Interim Report
四半期報告書-第25期第2四半期(2023/10/01-2023/12/31)
Japanese 163.0 KB
2023-11-10 08:00
Regulatory News Service
確認書
Japanese 8.0 KB
2023-11-10 07:51
Quarterly Report
四半期報告書-第25期第1四半期(2023/07/01-2023/09/30)
Japanese 134.0 KB
2023-09-27 08:08
Post-Annual General Meeting Information
臨時報告書
Japanese 22.4 KB

Automate Your Workflow. Get a real-time feed of all CanBas Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for CanBas Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Pluri Inc. Logo
Develops placenta-based cell therapeutics using a proprietary 3D cell-expansion platform.
Israel PLUR
A global supplier of generic APIs using AI to accelerate drug development.
South Korea 041910
Poltreg S.A. Logo
Pioneering T-regulatory cell therapies for autoimmune diseases like diabetes, MS, and ALS.
Poland PTG
PolyPeptide Group AG Logo
A global CDMO specializing in peptide and oligonucleotide APIs for pharma and biotech partners.
Switzerland PPGN
Develops sensitive point-of-care biomarker diagnostics for human and animal health.
South Korea 335810
A global CDEMO offering end-to-end solutions for antibody therapeutics and biologics.
South Korea 334970
Develops affordable biosimilars and novel antibody drugs for life-threatening diseases.
Singapore 950210
Develops protein-based immunotherapies for metabolic diseases, immune disorders, and cancer.
South Korea 296160
PROTEINA CO.,LTD. Logo
A biotech firm specializing in proteomics for drug discovery and diagnostics in oncology.
South Korea 468530
PROTIA INC. Logo
Develops IVD kits and instruments for allergy, POCT, infectious & autoimmune diseases.
South Korea 303360

Talk to a Data Expert

Have a question? We'll get back to you promptly.